InvestorsHub Logo
Followers 51
Posts 8879
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Sunday, 11/05/2023 12:15:29 AM

Sunday, November 05, 2023 12:15:29 AM

Post# of 13233
Moderna's potential RSV product could be successful since it would be the only one on the market available in a pre-filled syringe, making it very easy to administer.....

Moderna has also predicted that the 15 planned launches could bring in as much as $30 billion in sales in the coming years. And the company says its current balance sheet is strong enough to fund its plans, so it won't need to raise capital by selling shares.
Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News